Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Robert Wood Johnson Foundation | OTHER |
| University of California, Los Angeles | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators plan to compare the impact of two approaches for smoking cessation on smoking abstinence, use of evidenced-based therapy, and quality of life among a diverse population of patients at the Manhattan campus of the VA New York Harbor Healthcare System, which serves a critical safety-net role for urban veterans. During hospitalization, all smokers will receive usual care. Patients will be randomized to one of two arms: financial incentives plus usual care vs. usual care alone, which includes referral to the state Quitline. All patients enrolled in the study will be offered nicotine replacement therapy. The investigators will conduct follow-up assessments at 2 weeks, 2 months, 6 months and 12 months after discharge. The primary study outcome is smoking abstinence at 6-month follow-up, verified by salivary/urinary cotinine.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Usual care | Active Comparator | Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. |
|
| Financial Incentives | Experimental | Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Smoking cessation counseling (Quitline) | Behavioral |
| ||
| Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy) |
| Measure | Description | Time Frame |
|---|---|---|
| Smoking abstinence assessed by self-reported and biochemically verified by salivary cotinine | Assessed by self-report questionnaire, and biochemically verified by salivary cotinine | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Smoking abstinence assessed by self-report | Assessed by self-report questionnaire | 6 months |
| Use of evidence based treatment (e.g. counseling and smoking cessation medications) assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joseph Ladapo, MD, PhD | University of California, Los Angeles | Principal Investigator |
| Scott Sherman, MD, MPH | NYU Langone Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| New York University School of Medicine | New York | New York | 10016 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30463608 | Derived | French KM, Gonzalez SZ, Sherman SE, Link AR, Malik SZ, Tseng CH, Jumkhawala SA, Tejada B, White A, Ladapo JA. Financial IncEntives for Smoking TreAtment: protocol of the FIESTA trial and FIESTA Oral Microbiome Substudy. Trials. 2018 Nov 21;19(1):646. doi: 10.1186/s13063-018-3003-y. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012907 | Smoking |
| D000073869 | Tobacco Smoking |
| D014029 | Tobacco Use Disorder |
| ID | Term |
|---|---|
| D001519 | Behavior |
| D064424 | Tobacco Use |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000095488 | Nicotine Replacement Therapy |
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Behavioral |
|
| Financial incentives | Behavioral |
|
Assessed by discharge prescriptions, Quitline records, receipts, letters and/or self-report |
| 2 weeks and 2 months |
| Quality of life as measured by the EQ5-D and VR-12 | As measured by the EQ5-D and VR-12 | 6 months |
| Short term return on investment of using financial incentives to promote smoking cessation (Cost analysis) | Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization | 12 months |
| Long term return on investment of using financial incentives to promote smoking cessation (Cost analysis) | Cost analysis involving hospital utilization data, electronic health records and patient-reported healthcare utilization | 3 years |
| D001523 |
| Mental Disorders |